FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Thomas S. Lin, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Jennifer Webb, Sharon Waymer, Mollie E. Moran, Margaret S. Lucas, Sherif Farag, John C. Byrd

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The in vivo mechanism of action of alemtuzumab (anti-CD52; Campath-1H) remains unclear. With rituximab, FCGR3A and FCGR2A high-affinity polymorphisms have been associated with clinical response in lymphoma but not in CLL, suggesting potential divergent mechanisms of action between these 2 diseases. Herein, we examined FCGR3A (V/V, n = 4; V/F, n = 10; F/F, n = 19) and FCGR2A (A/A, n = 5; H/A, n = 22; H/H, n = 6) polymorphisms in 36 patients with relapsed CLL who were treated with thrice-weekly alemtuzumab for 12 weeks to assess the potential influence these high-affinity FcγR receptor polymorphisms had on response to alemtuzumab. Response to alemtuzumab was similar regardless of FCGR3A polymorphism (V/V, 25%; V/F, 40%; F/F, 32%) or FCGR2A polymorphism (A/A, 40%; H/A, 32%; H/H, 33%). These findings indicate that FCGR3A and FCGR2A polymorphisms may not predict response to alemtuzumab in CLL. Future studies examining larger cohorts of alemtuzumab-treated patients with CLL will be required to definitively determine the predictive value of specific FCGR polymorphisms to treatment response.

Original languageEnglish (US)
Pages (from-to)289-291
Number of pages3
JournalBlood
Volume105
Issue number1
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Polymorphism
alemtuzumab
Lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Lin, T. S., Flinn, I. W., Modali, R., Lehman, T. A., Webb, J., Waymer, S., ... Byrd, J. C. (2005). FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood, 105(1), 289-291. https://doi.org/10.1182/blood-2004-02-0651

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. / Lin, Thomas S.; Flinn, Ian W.; Modali, Rama; Lehman, Teresa A.; Webb, Jennifer; Waymer, Sharon; Moran, Mollie E.; Lucas, Margaret S.; Farag, Sherif; Byrd, John C.

In: Blood, Vol. 105, No. 1, 01.01.2005, p. 289-291.

Research output: Contribution to journalArticle

Lin, TS, Flinn, IW, Modali, R, Lehman, TA, Webb, J, Waymer, S, Moran, ME, Lucas, MS, Farag, S & Byrd, JC 2005, 'FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia', Blood, vol. 105, no. 1, pp. 289-291. https://doi.org/10.1182/blood-2004-02-0651
Lin, Thomas S. ; Flinn, Ian W. ; Modali, Rama ; Lehman, Teresa A. ; Webb, Jennifer ; Waymer, Sharon ; Moran, Mollie E. ; Lucas, Margaret S. ; Farag, Sherif ; Byrd, John C. / FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. In: Blood. 2005 ; Vol. 105, No. 1. pp. 289-291.
@article{68f358a130ae499da86e9236e65e7132,
title = "FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia",
abstract = "The in vivo mechanism of action of alemtuzumab (anti-CD52; Campath-1H) remains unclear. With rituximab, FCGR3A and FCGR2A high-affinity polymorphisms have been associated with clinical response in lymphoma but not in CLL, suggesting potential divergent mechanisms of action between these 2 diseases. Herein, we examined FCGR3A (V/V, n = 4; V/F, n = 10; F/F, n = 19) and FCGR2A (A/A, n = 5; H/A, n = 22; H/H, n = 6) polymorphisms in 36 patients with relapsed CLL who were treated with thrice-weekly alemtuzumab for 12 weeks to assess the potential influence these high-affinity FcγR receptor polymorphisms had on response to alemtuzumab. Response to alemtuzumab was similar regardless of FCGR3A polymorphism (V/V, 25{\%}; V/F, 40{\%}; F/F, 32{\%}) or FCGR2A polymorphism (A/A, 40{\%}; H/A, 32{\%}; H/H, 33{\%}). These findings indicate that FCGR3A and FCGR2A polymorphisms may not predict response to alemtuzumab in CLL. Future studies examining larger cohorts of alemtuzumab-treated patients with CLL will be required to definitively determine the predictive value of specific FCGR polymorphisms to treatment response.",
author = "Lin, {Thomas S.} and Flinn, {Ian W.} and Rama Modali and Lehman, {Teresa A.} and Jennifer Webb and Sharon Waymer and Moran, {Mollie E.} and Lucas, {Margaret S.} and Sherif Farag and Byrd, {John C.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1182/blood-2004-02-0651",
language = "English (US)",
volume = "105",
pages = "289--291",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

AU - Lin, Thomas S.

AU - Flinn, Ian W.

AU - Modali, Rama

AU - Lehman, Teresa A.

AU - Webb, Jennifer

AU - Waymer, Sharon

AU - Moran, Mollie E.

AU - Lucas, Margaret S.

AU - Farag, Sherif

AU - Byrd, John C.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The in vivo mechanism of action of alemtuzumab (anti-CD52; Campath-1H) remains unclear. With rituximab, FCGR3A and FCGR2A high-affinity polymorphisms have been associated with clinical response in lymphoma but not in CLL, suggesting potential divergent mechanisms of action between these 2 diseases. Herein, we examined FCGR3A (V/V, n = 4; V/F, n = 10; F/F, n = 19) and FCGR2A (A/A, n = 5; H/A, n = 22; H/H, n = 6) polymorphisms in 36 patients with relapsed CLL who were treated with thrice-weekly alemtuzumab for 12 weeks to assess the potential influence these high-affinity FcγR receptor polymorphisms had on response to alemtuzumab. Response to alemtuzumab was similar regardless of FCGR3A polymorphism (V/V, 25%; V/F, 40%; F/F, 32%) or FCGR2A polymorphism (A/A, 40%; H/A, 32%; H/H, 33%). These findings indicate that FCGR3A and FCGR2A polymorphisms may not predict response to alemtuzumab in CLL. Future studies examining larger cohorts of alemtuzumab-treated patients with CLL will be required to definitively determine the predictive value of specific FCGR polymorphisms to treatment response.

AB - The in vivo mechanism of action of alemtuzumab (anti-CD52; Campath-1H) remains unclear. With rituximab, FCGR3A and FCGR2A high-affinity polymorphisms have been associated with clinical response in lymphoma but not in CLL, suggesting potential divergent mechanisms of action between these 2 diseases. Herein, we examined FCGR3A (V/V, n = 4; V/F, n = 10; F/F, n = 19) and FCGR2A (A/A, n = 5; H/A, n = 22; H/H, n = 6) polymorphisms in 36 patients with relapsed CLL who were treated with thrice-weekly alemtuzumab for 12 weeks to assess the potential influence these high-affinity FcγR receptor polymorphisms had on response to alemtuzumab. Response to alemtuzumab was similar regardless of FCGR3A polymorphism (V/V, 25%; V/F, 40%; F/F, 32%) or FCGR2A polymorphism (A/A, 40%; H/A, 32%; H/H, 33%). These findings indicate that FCGR3A and FCGR2A polymorphisms may not predict response to alemtuzumab in CLL. Future studies examining larger cohorts of alemtuzumab-treated patients with CLL will be required to definitively determine the predictive value of specific FCGR polymorphisms to treatment response.

UR - http://www.scopus.com/inward/record.url?scp=19944425937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944425937&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-02-0651

DO - 10.1182/blood-2004-02-0651

M3 - Article

VL - 105

SP - 289

EP - 291

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -